Genmab A/S / Merus N.V.

Head and Neck Squamous Cell Carcinoma (HNSCC/SCCHN)

66K US cases/yr · $4.5B Global HNSCC therapeutics market 2030E · ~15,000 Annual US HNSCC deaths

Disease Overview

Head and neck squamous cell carcinoma (HNSCC or SCCHN) arises from the mucosal epithelium of the oral cavity, pharynx and larynx and is the sixth most common cancer globally. Risk factors include tobacco and alcohol exposure and, increasingly, high-risk oncogenic HPV (notably HPV-16) which now drives the majority of oropharyngeal cases in high-income countries. Despite multimodal therapy (surgery, radiation, cisplatin-based chemoradiation and cetuximab), five-year survival remains modest for locally advanced disease and dismal for recurrent/metastatic (R/M) disease, with median overall survival of approximately 12-15 months on current first-line PD-1 with or without chemotherapy regimens. Roughly 66,000 new US cases and 15,000 deaths occur annually. First-line R/M treatment is dominated by pembrolizumab monotherapy (PD-L1 CPS >=1) or pembrolizumab + platinum/5-FU based on KEYNOTE-048. Second-line options are limited: cetuximab + chemotherapy, taxanes, or clinical trials. The clear unmet need is novel mechanisms that improve depth and durability of response in post-PD-(L)1 relapsed disease, particularly HPV-negative tumors where EGFR pathway dependence and Wnt/LGR5 stemness drive resistance.

Competitive Landscape

First-line recurrent/metastatic HNSCC is anchored by Keytruda (pembrolizumab, Merck, anti-PD-1) as monotherapy in PD-L1 CPS >=1 patients and in combination with platinum/5-FU per KEYNOTE-048, with Opdivo (nivolumab, BMS, anti-PD-1) also approved in platinum-refractory disease. Cetuximab (Erbitux, Eli Lilly/Merck KGaA, anti-EGFR chimeric mAb) remains the principal EGFR-directed agent in combination with radiation (locally advanced) or chemotherapy (R/M). Emerging bispecifics and novel targets are reshaping later lines: petosemtamab (MCLA-158, Merus/Genmab) is a first-in-class EGFR x LGR5 IgG1 bispecific that simultaneously drives EGFR internalization/degradation and targets LGR5+ cancer stem cells, with two FDA Breakthrough Therapy Designations (2L+ HNSCC monotherapy 2024; 1L HNSCC + pembrolizumab 2024) and Phase 2 ASCO 2025 readouts showing ORR substantially above SoC. Additional competitors include ficlatuzumab (AVEO, anti-HGF), cemiplimab (Libtayo, Regeneron, anti-PD-1, CSCC approved), tipifarnib (Kura, HRAS-mutant HNSCC), xevinapant (Merck KGaA, IAP inhibitor, locally advanced), eftilagimod alpha (Immutep, LAG-3 agonist) and multiple TIGIT, LAG-3 and HPV-directed TCR/vaccine programs. Oncolytic and antibody-drug conjugate (ADC) strategies targeting HER3, TROP2 and Nectin-4 are advancing in Phase 1/2.